



I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents, Box 1450, P.O. Box 1450, Alexandria, VA 22314-1450 on this day of May, 2004.

to: Commissioner of Patents, Box 1450, P.O. Box 1450, Alexandria, VA 22315-1459 on this day of May, 2004.												
Ву	(Signature of person mailing) Andrea E. Dorigo											
	(Typed or printed name of person)											
	IN THE UNITED STATES PATENT A	ND TRA	ADEMARK OFFICE									
IN RE API	PLICATION OF: Lee et al.	:										
APPLICA	ΓΙΟΝ NO.: 10/626,275	:	Examiner:									
FILING D	ATE: July 25, 2002	:	Group Art Unit: 1614									
TITLE:	PRAMIPEXOLE ONCE-DAILY DOSAGE FORM	:										
Commissio	oner for Patents											

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO-FB-A820 form is not intended to represent or imply that these references are prior art to the above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Andrea E. Dorigo

Attorney for Applicant(s)

Reg. No. 47,532

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755

(212) 733-1898

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: $\leq /3/\sqrt{9}$

Andrea E. Dorigo

Attorney for Applicant(s)

Reg. No. 47,532

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 733-1898

INFORMATION PISCE QSURE CITATION						AT	ATTY. DOCKET NO. PC28017 SERIAL NO. 10/626,27							75	
(Use several sheet necessary)							APPLICANT Lee et al.								
MAY 0 5 2004 5						FIL	FILING DATE July 25, 2002 GROUP 1614						4		
U.S. PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE APPROPRIATE															
EXAMINER INITIAL	N. C.	TRADE	ARI	DOC	CUMENT NU	MBER	,		DATE	NAME	CLAS	S SUBCLASS	FILING IF APPROF	DATE PRIATE	
	a)	6	2	7	7	8	7	5	8/21/01	Holman, Andre	ew J. 514	367			
	b)	4	7	3	1	3	7	4	3/15/88	Griss et al		367			
	c)	0	0	1	5	7	3	5	2/7/02	Hedden et a		488			
	d)	6	0	5	6	9	7	7	5/2/00	Bhagwat et	al. 424	488			
	e)	5	4	7	2	7	1	2	12/5/95	Oshlack et a		480			
FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER						DATE	COUNTRY	CLAS	S SUBCLASS	TRANSL	ATION				
													YES	NO	
	f)	0	1	2	2	8	2	0	4/5/01	wo	A01	N 43/78			
	g)	9	9	1	6	4	4	2	4/8/99	wo	A61	к			
	h)	9	9	0	9	0	6	6	2/25/99	wo	C08	B A61K			
	i)	9	9	4	5	9	2	4	9/16/99	wo	A61	ĸ			
	j)	0	0	5	9	4	7	7	10/12/00	wo	A61	к			
	k)	9	7	0	4	7	5	2	2/13/97	wo	A61	ĸ			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
ı)	Hubb	Hubble et al. (1995), Clinical Neuropharmacology 18(4), 338–347												
	n)					•									
			Dooley & Markham (1998), <i>Drugs & Aging</i> 12(6), 495–514												
<u> n</u>	1)	Bigla	Biglan & Holloway (2002), Expert Opinion on Pharmacotherapy 3(2), 197–210												
c))	Wrigi	Wright et al. (1997), Journal of Clinical Pharmacology 37, 520–525												
ρ)	United States Pharmacopeia 24th edition (2000) (USP 24), pp. 1941–1943													
q	1)	Colos	simo &	De Mich	nele (19	99), <i>E</i> t	ıropean .	Journal (of Neurolo	ogy 6(1), 1–2°	I				
EXAMINE	q) Colosimo & De Michele (1999), European Journal of Neurology 6(1), 1–21 EXAMINER DATE CONSIDERED														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE